EP300 detection preparation and application of EP300 in product for treating rheumatoid arthritis

By synthesizing the Si-EP300 sequence of a specific small interfering gene and regulating H3K18 lactation, the problems of target generalization and drug resistance in the treatment of rheumatoid arthritis have been solved, providing an effective molecular targeted therapy tool for the diagnosis and treatment of rheumatoid arthritis.

CN121294640APending Publication Date: 2026-01-09ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE +1
1 Cites 0 Cited by

Patent Information

Application Number
CN202511461401.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-14
Publication Date
2026-01-09

AI Technical Summary

Technical Problem

Existing drugs for the treatment of rheumatoid arthritis mostly target single inflammatory factors or immune cells, which have problems such as target generalization and easy development of drug resistance, and lack innovative drug targets and mechanisms.

Method used

We designed and synthesized the Si-EP300 sequence, a specific small interfering gene, which inhibits the proliferation of human monocytes/macrophages and synovial fibroblasts and the expression of pathological markers in rheumatoid arthritis by regulating H3K18 lactation, and provides EP300 detection agents and therapeutic products.

Benefits of technology

Significantly reducing the expression of inflammatory markers MMP3 and Fibronectin in synovial cells, decreasing synovial cell proliferation, and increasing apoptosis rate, it has become a molecular targeted therapy tool for rheumatoid arthritis, used for early diagnosis, targeted therapy, and prognostic assessment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides an EP300 detection preparation and application of EP300 in a product for treating rheumatoid arthritis, and relates to the technical field of biological medicines. The rheumatoid arthritis symptom is relieved by inhibiting EP300 gene expression, after EP300 is knocked down in human THP-1-derived macrophages, H3K18 lactylation expression is reduced, and after EP300 is knocked down in human THP-1-derived macrophages, EP300 and human synovial cells are co-cultured, so that the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, and the human THP-1-derived macrophages are obtained. Through the crosstalk effect between human THP-1-derived macrophages and human synovial cells, the expression of inflammatory markers MMP3 and Fibronectin in the synovial cells can be remarkably inhibited, compared with a model group, the proliferation capacity of the synovial cells is weakened, a potential treatment target is provided for treating rheumatoid arthritis, and the application has the advantages that the application is easy to popularize and use, and the application has a wide application prospect. The pathogenesis of rheumatoid arthritis is perfected, and hope is brought to research and development of novel biomarkers for early diagnosis, targeted therapy and prognosis evaluation of rheumatoid arthritis.
Need to check novelty before this filing date? Find Prior Art